Bosentan for chronic thromboembolic pulmonary hypertension: Findings from a systematic review and meta-analysis

2010 ◽  
Vol 126 (1) ◽  
pp. e51-e56 ◽  
Author(s):  
Cecilia Becattini ◽  
Giorgia Manina ◽  
Chiara Busti ◽  
Silvia Gennarini ◽  
Giancarlo Agnelli
BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e038385
Author(s):  
Liyan Zhang ◽  
Peijing Yan ◽  
Kehu Yang ◽  
Shanlian Wu ◽  
Yuping Bai ◽  
...  

ObjectiveWhether splenectomy increases the risk of chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. We conducted a systematic review and meta-analysis to explore the association between splenectomy and CTEPH.DesignSystematic review and meta-analysis.Data sourcesPubMed, Embase and Cochrane Library databases.MethodsTwo authors independently searched and extracted the data. The Newcastle-Ottawa Scale and the Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used to assess the quality of the included studies, and each quality item was graded as low risk or high risk. A random-effects model was used to calculate different effective values.ResultsIn total, 8 trials involving 6183 participants fulfilled the inclusion criteria. The overall pooled crude prevalence of splenectomy was 4.0% (95% CI 0.03 to 0.06, I2=71.5%, p<0.001) in patients with CTEPH. Subgroup analysis showed a statistically significant high incidence of splenectomy in patients with CTEPH (OR=2.94, 95% CI 1.62 to 5.33, I2=0.0%, p<0.001) compared with patients with pulmonary arterial hypertension. There was a significantly high incidence of splenectomy in patients with CTEPH (OR=5.59, 95% CI 2.12 to 14.74, I2=0.0%, p<0.001) compared with patients with thromboembolism disease (venous thromboembolism or pulmonary embolism).ConclusionThe prevalence of splenectomy in patients with CTEPH was 4.0% and CTEPH might be associated with splenectomy. However, high-quality prospective trials are needed.PROSPERO registration numberCRD42020137591.


Sign in / Sign up

Export Citation Format

Share Document